

AVSOLA[®] Billing and Coding Guide

AVSOLA[®] is a biosimilar to Remicade[®]
backed by Amgen expertise¹



FOR PHYSICIAN OFFICES USING THE CMS 1500



FOR HOSPITALS/INSTITUTIONS USING THE CMS 1450



Call Amgen[®] SupportPlus for assistance with specific payer requirements: **(866)-264-2778**, Monday - Friday, 9 am - 8 pm ET

For 340B Modifier: Beginning January 1, 2023, Medicare requires that all claims submitted by 340B covered entities on OPPS claims (bill type 13X) for separately payable Part B drugs and biologicals must include modifiers “JG” (Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes) or “TB” (Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes for select entities) on claim lines for drugs acquired through the 340B Drug Discount Program. Additional provider types will be required to use these modifiers in 2024.²

INDICATIONS

AVSOLA[®] is indicated for:

- **Crohn’s Disease:** Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. AVSOLA[®] is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease.
- **Pediatric Crohn’s Disease:** Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
- **Ulcerative Colitis:** Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
- **Pediatric Ulcerative Colitis:** Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
- **Rheumatoid Arthritis in combination with methotrexate:** Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- **Ankylosing Spondylitis:** Reducing signs and symptoms in adult patients with active ankylosing spondylitis.
- **Psoriatic Arthritis:** Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis.
- **Plaque Psoriasis:** The treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. AVSOLA[®] should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.



Please see full Important Safety Information on pages 6-7.

BILLING AND CODING

NATIONAL DRUG CODE (NDC)¹

55513-670-01	10-digit NDC	Single-dose vial containing 100 mg of AVSOLA [®] for final reconstitution volume of 10 mL
55513-0670-01	11-digit NDC	

HCPCS^{2,3}

Q5121 Injection, infliximab-axxq, biosimilar, (AVSOLA [®]), 10 mg
--

JW/JZ Modifier in Box 24D[†]	Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use vials and containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers. [†]
--	---

Healthcare providers should consult the payer or Medicare contractor to determine which CPT[®] code(s) is most appropriate for administration of AVSOLA[®]. The codes listed below are not an exhaustive list of drug administration services. Please refer to the CPT[®] manual for a complete list of drug administration codes.

[†]Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

CPT^{®5}

96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour. (List separately in addition to code for primary procedure)
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour. (List separately in addition to code for primary procedure)

REVENUE CODES⁶ (hospital setting only)

0636 Drugs requiring detailed coding	0250 General pharmacy
---	------------------------------

AVSOLA[®] BILLING UNITS

Number of 100 mg vials of AVSOLA [®]	Total milligrams (mg)	Number of Q5121 billing units (10 mg infliximab-axxq biosimilar per unit)
1	100	10 units
2	200	20 units
3	300	30 units
4	400	40 units
5	500	50 units

SELECT IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal side effects have been reported with infliximab products. Infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens (eg, TB, histoplasmosis) have been reported. Lymphoma, including cases of fatal hepatosplenic T-cell lymphoma (HSTCL), and other malignancies have been reported, including in children and young adult patients. Due to the risk of HSTCL, mostly reported in Crohn's disease and ulcerative colitis, assess the risk/benefit, especially if the patient is male and is receiving azathioprine or 6-mercaptopurine treatment. AVSOLA[®] is contraindicated at doses >5 mg/kg in patients with moderate or severe heart failure and in patients with severe hypersensitivity reactions to infliximab. Other serious side effects reported include melanoma, Merkel cell carcinoma, invasive cervical cancer, hepatitis B reactivation, hepatotoxicity, hematological events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurological events, and lupus-like syndrome. Please see related and other Important Safety Information on pages 6-7.

BILLING AND CODING (cont'd)

The ICD-10-CM codes provided below are not an exhaustive list, and payers may require a higher level of specificity. Please refer to the ICD-10-CM manual for a complete list of diagnosis codes, including those with complications.

COMMON ICD-10-CM CODES ⁷	
MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE	
K50.00	Crohn's disease of small intestine without complications
K50.10	Crohn's disease of large intestine without complications
K50.80	Crohn's disease of both small and large intestine without complications
K50.90	Crohn's disease, unspecified, without complications
FISTULA (use in addition to codes for Crohn's disease)	
K60.3	Anal fistula
K60.4	Rectal fistula
MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS	
K51.00	Ulcerative (chronic) pancolitis without complications
K51.20	Ulcerative (chronic) proctitis without complications
K51.30	Ulcerative (chronic) rectosigmoiditis without complications
K51.50	Left-sided colitis without complications
K51.80	Other ulcerative colitis without complications
K51.90	Ulcerative colitis, unspecified, without complications
MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS	
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site
ACTIVE ANKYLOSING SPONDYLITIS	
M45.9	Ankylosing spondylitis of unspecified sites in spine
ACTIVE PSORIATIC ARTHRITIS	
L40.50	Arthropathic psoriasis, unspecified
CHRONIC SEVERE PLAQUE PSORIASIS	
L40.0	Psoriasis vulgaris

The information provided in this document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this document should in no way be considered a guarantee of coverage or reimbursement for any product or service.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

American Medical Association. Current Procedural Terminology (CPT®) 2020 Professional Edition. Copyright © 2019 American Medical Association. All rights reserved.





PHYSICIAN CODING FORM

The CMS 1500 for Physician Office

Sample CMS 1500 Form — Physician Office Administration

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

PICA PICA

1. MEDICARE MEDICAID TRICARE CHAMPVA GROUP HEALTH PLAN FECA BLK LUNG OTHER

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)
Doe, John D

3. PATIENT'S BIRTH DATE
MM | DD | YY
xx | xx | xx SEX M F

4. INSURED'S NAME (Last Name, First Name, Middle Initial)
Doe, John D

5. PATIENT'S ADDRESS (No., Street)
5555 Any Street

6. PATIENT RELATIONSHIP TO INSURED
Self Spouse Child Other

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary for the payment of medical benefits to the undersigned physician or supplier for services described below.

13. SIGNED

14. DATE

15. FROM

16. DATES FROM

17. HOSPITAL

18. FROM

19. OUTSIDE

20. YES NO

21. RESUB CODE

22. PRIOR AUTHORIZATION

23. PRIOR AUTHORIZATION

24. A. DATE(S) OF SERVICE From To B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS OR UNITS H. EPSON Family Plan I. ID. QUAL. J. RENDERING PROVIDER ID. #

	From	To	Place of Service	EMG	Procedure, Service, or Supplies	Diagnosis Pointer	\$ Charges	Days or Units	EPSON Family Plan	ID. Qual.	Rendering Provider ID. #				
1	xx	xx	xx	xx	xx	xx	11	Q5121		A	xxx	xx	#		NPI
2	xx	xx	xx	xx	xx	xx	11	Q5121	JW	A	xxx	xx	#		NPI
3	xx	xx	xx	xx	xx	xx	11	96XXX		A	xxx	xx	#		NPI
4	xx	xx	xx	xx	xx	xx	11	96XXX		A	xxx	xx	#		NPI

25. USE

26. USE

27. USE

28. USE

29. USE

30. USE

31. USE

32. USE

33. USE

34. USE

35. USE

36. USE

37. USE

38. USE

39. USE

40. USE

41. USE

42. USE

43. USE

44. USE

45. USE

46. USE

47. USE

48. USE

49. USE

50. USE

51. USE

52. USE

53. USE

54. USE

55. USE

56. USE

57. USE

58. USE

59. USE

60. USE

61. USE

62. USE

63. USE

64. USE

65. USE

66. USE

67. USE

68. USE

69. USE

70. USE

71. USE

72. USE

73. USE

74. USE

75. USE

76. USE

77. USE

78. USE

79. USE

80. USE

81. USE

82. USE

83. USE

84. USE

85. USE

86. USE

87. USE

88. USE

89. USE

90. USE

91. USE

92. USE

93. USE

94. USE

95. USE

96. USE

97. USE

98. USE

99. USE

100. USE

101. USE

102. USE

103. USE

104. USE

105. USE

106. USE

107. USE

108. USE

109. USE

110. USE

111. USE

112. USE

113. USE

114. USE

115. USE

116. USE

117. USE

118. USE

119. USE

120. USE

121. USE

122. USE

123. USE

124. USE

125. USE

126. USE

127. USE

128. USE

129. USE

130. USE

131. USE

132. USE

133. USE

134. USE

135. USE

136. USE

137. USE

138. USE

139. USE

140. USE

141. USE

142. USE

143. USE

144. USE

145. USE

146. USE

147. USE

148. USE

149. USE

150. USE

151. USE

152. USE

153. USE

154. USE

155. USE

156. USE

157. USE

158. USE

159. USE

160. USE

161. USE

162. USE

163. USE

164. USE

165. USE

166. USE

167. USE

168. USE

169. USE

170. USE

171. USE

172. USE

173. USE

174. USE

175. USE

176. USE

177. USE

178. USE

179. USE

180. USE

181. USE

182. USE

183. USE

184. USE

185. USE

186. USE

187. USE

188. USE

189. USE

190. USE

191. USE

192. USE

193. USE

194. USE

195. USE

196. USE

197. USE

198. USE

199. USE

200. USE

201. USE

202. USE

203. USE

204. USE

205. USE

206. USE

207. USE

208. USE

209. USE

210. USE

211. USE

212. USE

213. USE

214. USE

215. USE

216. USE

217. USE

218. USE

219. USE

220. USE

221. USE

222. USE

223. USE

224. USE

225. USE

226. USE

227. USE

228. USE

229. USE

230. USE

231. USE

232. USE

233. USE

234. USE

235. USE

236. USE

237. USE

238. USE

239. USE

240. USE

241. USE

242. USE

243. USE

244. USE

245. USE

246. USE

247. USE

248. USE

249. USE

250. USE

251. USE

252. USE

253. USE

254. USE

255. USE

256. USE

257. USE

258. USE

259. USE

260. USE

261. USE

262. USE

263. USE

264. USE

265. USE

266. USE

267. USE

268. USE

269. USE

270. USE

271. USE

272. USE

273. USE

274. USE

275. USE

276. USE

277. USE

278. USE

279. USE

280. USE

281. USE

282. USE

283. USE

284. USE

285. USE

286. USE

287. USE

288. USE

289. USE

290. USE

291. USE

292. USE

293. USE

294. USE

295. USE

296. USE

297. USE

298. USE

299. USE

300. USE

301. USE

302. USE

303. USE

304. USE

305. USE

306. USE

307. USE

308. USE

309. USE

310. USE

311. USE

312. USE

313. USE

314. USE

315. USE

316. USE

317. USE

318. USE

319. USE

320. USE

321. USE

322. USE

323. USE

324. USE

325. USE

326. USE

327. USE

328. USE

329. USE

330. USE

331. USE

332. USE

333. USE

334. USE

335. USE

336. USE

337. USE

338. USE

339. USE

340. USE

341. USE

342. USE

343. USE

344. USE

345. USE

346. USE

347. USE

348. USE

349. USE

350. USE

351. USE

352. USE

353. USE

354. USE

355. USE

356. USE

357. USE

358. USE

359. USE

360. USE

361. USE

362. USE

363. USE

364. USE

365. USE

366. USE

367. USE

368. USE

369. USE

370. USE

371. USE

372. USE

373. USE

374. USE

375. USE

376. USE

377. USE

378. USE

379. USE

380. USE

381. USE

382. USE

383. USE

384. USE

385. USE

386. USE

387. USE

388. USE

389. USE

390. USE

391. USE

392. USE

393. USE

394. USE

395. USE

396. USE

397. USE

398. USE

399. USE

400. USE

401. USE

402. USE

403. USE

404. USE

405. USE

406. USE

407. USE

408. USE

409. USE

410. USE

411. USE

412. USE

413. USE

414. USE

415. USE

416. USE

417. USE

418. USE

419. USE

420. USE

421. USE

422. USE

423. USE

424. USE

425. USE

426. USE

427. USE

428. USE

429. USE

430. USE

431. USE

432. USE

433. USE

434. USE

435. USE

436. USE

437. USE

438. USE

439. USE

440. USE

441. USE

442. USE

443. USE

444. USE

445. USE

446. USE

447. USE

448. USE

449. USE

450. USE

451. USE

452. USE

453. USE

454. USE

455. USE

456. USE

457. USE

458. USE

459. USE

460. USE

461. USE

462. USE

463. USE

464. USE

465. USE

466. USE

467. USE

468. USE

469. USE

470. USE

471. USE

472. USE

473. USE

474. USE

475. USE

476. USE

477. USE

478. USE

479. USE

480. USE

481. USE

482. USE

483. USE

484. USE

485. USE

486. USE

487. USE

488. USE

489. USE

490. USE

491. USE

492. USE

493. USE

494. USE

495. USE

496. USE

497. USE

498. USE

499. USE

500. USE

501. USE

502. USE

503. USE

504. USE

505. USE

506. USE

507. USE

508. USE

509. USE

510. USE

511. USE

512. USE

513. USE

514. USE

515. USE

516. USE

517. USE

518. USE

519. USE

520. USE

521. USE

522. USE

523. USE

524. USE

525. USE

526. USE

527. USE

528. USE

529. USE

530. USE

531. USE

532. USE

533. USE

534. USE

535. USE

536. USE

537. USE

538. USE

539. USE

540. USE

541. USE

542. USE

543. USE

544. USE

545. USE

546. USE

547. USE

548. USE

549. USE

550. USE

551. USE

552. USE

553. USE

554. USE

555. USE

556. USE

557. USE

558. USE

559. USE

560. USE

561. USE

562. USE

563. USE

564. USE

565. USE

566. USE

567. USE

568. USE

569. USE

570. USE

571. USE

572. USE

573. USE

574. USE

575. USE

576. USE

577. USE

578. USE

579. USE

580. USE

581. USE

582. USE

583. USE

584. USE

585. USE

586. USE

587. USE

588. USE

589. USE

590. USE

591. USE

592. USE

593. USE

594. USE

595. USE

596. USE

597. USE

598. USE

599. USE

600. USE

601. USE

602. USE

603. USE

604. USE

605. USE

606. USE

607. USE

608. USE

609. USE

610. USE

611. USE

612. USE

613. USE

614. USE

615. USE

616. USE

617. USE

618. USE

619. USE

620. USE

621. USE

622. USE

623. USE

624. USE

625. USE

626. USE

627. USE

628. USE

629. USE

630. USE

631. USE

632. USE

633. USE

634. USE

635. USE

636. USE

637. USE

638. USE

639. USE

640. USE

641. USE

642. USE

643. USE

644. USE

645. USE

646. USE

647. USE

648. USE

649. USE

650. USE

651. USE

652. USE

653. USE

654. USE

655. USE

656. USE

657. USE

658. USE

659. USE

660. USE

661. USE

662. USE

663. USE

664. USE

665. USE

666. USE

667. USE

668. USE

669. USE

670. USE

671. USE

672. USE

673. USE

674. USE

675. USE

676. USE

677. USE

678. USE

679. USE

680. USE

681. USE

682. USE

683. USE

684. USE

685. USE

686. USE

687. USE

688. USE

689. USE

690. USE

691. USE

692. USE

693. USE

694. USE

695. USE

696. USE

697. USE

698. USE

699. USE

700. USE

701. USE

702. USE

703. USE

704. USE

705. USE

706. USE

707. USE

708. USE

709. USE

710. USE

711. USE

712. USE

713. USE

714. USE

715. USE

716. USE

717. USE

718. USE

719. USE

720. USE

721. USE

722. USE

723. USE

724. USE

725. USE

726. USE

727. USE

728. USE

729. USE

730. USE

731. USE

732. USE

733. USE

734. USE

735. USE

736. USE

737. USE

738. USE

739. USE

740. USE

741. USE

742. USE

743. USE

744. USE

745. USE

746. USE

747. USE

748. USE

749. USE

750. USE

751. USE

752. USE

753. USE

754. USE

755. USE

756. USE

757. USE

758. USE

759. USE

760. USE

761. USE

762. USE

763. USE

764. USE

765. USE

766. USE

767. USE

768. USE

769. USE

770. USE

771. USE

772. USE

773. USE

774. USE

775. USE

776. USE

777. USE

778. USE

779. USE

780. USE

781. USE

782. USE

783. USE

784. USE

785. USE

786. USE

787. USE

788. USE

789. USE

790. USE

791. USE

792. USE

793. USE

794. USE

795. USE

796. USE

797. USE

798. USE

799. USE

800. USE

801. USE

802. USE

803. USE

804. USE

805. USE

806. USE

807. USE

808. USE

809. USE

810. USE

811. USE

812. USE

813. USE

814. USE

815. USE

816. USE

817. USE

818. USE

819. USE

820. USE

821. USE

822. USE

823. USE

824. USE

825. USE

826. USE

827. USE

828. USE

829. USE

830. USE

831. USE

832. USE

833. USE

834. USE

835. USE

836. USE

837. USE

838. USE

839. USE

840. USE

841. USE

842. USE

843. USE

844. USE

845. USE

846. USE

847. USE

848. USE

849. USE

850. USE

851. USE

852. USE

853. USE

854. USE

855. USE

856. USE

857. USE

858. USE

859. USE

860. USE

861. USE

862. USE

863. USE

864. USE

865. USE

866. USE

867. USE

868. USE

869. USE

870. USE

871. USE

872. USE

873. USE

874. USE

875. USE

876. USE

877. USE

878. USE

879. USE

880. USE

881. USE

882. USE

883. USE

884. USE

885. USE

886. USE

887. USE

888. USE

889. USE

890. USE

891. USE

892. USE

893. USE

894. USE

895. USE

896. USE

897. USE

898. USE

899. USE

900. USE

901. USE

902. USE

903. USE

904. USE

905. USE

906. USE

907. USE

908. USE

909. USE

910. USE

911. USE

912. USE

913. USE

914. USE

915. USE

916. USE

917. USE

918. USE

919. USE

920. USE

921. USE

922. USE

923. USE

924. USE

925. USE

926. USE

927. USE

928. USE

929. USE

930. USE

931. USE

932. USE

933. USE

934. USE

935. USE

936. USE

937. USE

938. USE

939. USE

940. USE

941. USE

942. USE

943. USE

944. USE

945. USE

946. USE

947. USE

948. USE

949. USE

950. USE

951. USE

952. USE

953. USE

954. USE

955. USE

956. USE

957. USE

958. USE

959. USE

960. USE

961. USE

962. USE

963. USE

964. USE

965. USE

966. USE

967. USE

968. USE

969. USE

970. USE

971. USE

972. USE

973. USE

974. USE

975. USE

976. USE

977. USE

978. USE

979. USE

980. USE

981. USE

982. USE

983. USE

984. USE

985. USE

986. USE

987. USE

988. USE

989. USE

990. USE

991. USE

992. USE

993. USE

994. USE

995. USE

996. USE

997. USE

998. USE

999. USE

1000. USE

(BOX 19) ADDITIONAL CLAIM INFORMATION
AVSOLA® (infliximab-axxq), 100 mg.

(BOX 21) DIAGNOSIS CODE
Document appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Line A — primary diagnosis code.

(BOX 24E) DIAGNOSIS CODE
Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D.



HOSPITAL CODING FORM

The CMS 1450 for Hospital Outpatient

Sample UB-04 (CMS 1450) Form — Hospital Outpatient Administration

Anytown Hospital
100 Main Street
Anytown, Anystate 01010

3a PAT. CNTL. #
b. MED. REC. #
5 FED. TAX NO.
6 STATEMENT COVERS PERIOD FROM THROUGH
7

8 PATIENT NAME: **Smith, Jane**
9 PATIENT ADDRESS: **Anytown, Anystate 12345**

4 TYPE OF BILL

(BOX 42) REVENUE CODES
Product
Medicare: Use revenue code 0636. Drugs requiring detailed coding. Other payers: Use revenue code 0250. General pharmacy (or 0636, if required by a given payer).
Related administration procedure
Use most appropriate revenue code for cost center where service was performed (eg, 0510, Clinic).

(BOX 46) SERVICE UNITS
Report units of service for AVSOLA® in accordance with the code descriptor (i.e., 1 service unit = 10 mg). The service units for the line item with the JW modifier (when applicable) should reflect the unused portion of the single-dose vial.

(BOX 47) TOTAL CHARGES
Report appropriate charge for each line item.

42 REV. CD.	43 DESCRIPTION	44 HCPCS / RATE / HIPPS CODE	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES	49
0636	AVSOLA® infliximab-axxq	Q5121	MMDYY #	#	XXXXX		1
0636	AVSOLA® infliximab-axxq	Q5121JW	MMDYY #	#	XXXXX		2
0510	Clinic	96XXX	MMDYY #	#	XXXXX		3
0510	Clinic	96XXX	MMDYY #	#	XXXXX		4

(BOX 43) DESCRIPTION
Enter description for each revenue code.
If NDC reporting is required (for example, for Medicaid and some commercial payers), enter the NDC information for AVSOLA® in the shaded portion of Box 24A using the following format: N455513067001 UN1 (the last digit indicates the number of single-dose vials; for example, UN1 = 1 vial, UN2 = 2 vials, etc).

(BOX 44) PRODUCT AND PROCEDURE CODES
Product
Report HCPCS code Q5121 (Injection, infliximab-axxq, biosimilar, [AVSOLA®], 10 mg). Medicare requires use of the JW modifier (Drug amount discarded/not administered to any patient) when applicable. Other payers may have similar requirements.
Related administration procedure
Report the infusion service using the appropriate drug administration CPT code(s). Healthcare providers should consult the payer or Medicare contractor to determine which CPT code(s) is most appropriate for administration of AVSOLA®.
JW/JZ Discard Modifier — JW or JZ modifier required following HCPCS code (i.e., JXXXX-XX) for Medicare Part B claims for drugs in single-use containers.

(BOX 67) DIAGNOSIS CODES
Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis.

50 PAYER NAME
51 HEALTH PLAN ID
57 OTHER PRV ID
58 INSURED'S NAME
59 P. REL.
60 INSURED'S UNIQUE ID
61 GROUP NAME
62 INSURANCE GROUP NO.
64 DOCUMENT CONTROL NUMBER
65 EMPLOYER NAME
66 DX: **XXX.XX**

69 ADMIT DX
70 PATIENT REASON DX
71 PPS CODE
72 ECI
73
74 PRINCIPAL PROCEDURE CODE
75 OTHER PROCEDURE CODE
76 ATTENDING NPI
77 OPERATING NPI
78 OTHER NPI
79 OTHER NPI
80 REMARKS
81CCI

UB-04 CMS-1450 APPROVED OMB NO. 0938-0997 NUBC® National Uniform Billing Committee THE CERTIFICATIONS ON THE REVERSE APPLY TO THIS BILL AND ARE MADE A PART HEREOF.

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.



IMPORTANT SAFETY INFORMATION

SERIOUS INFECTIONS: Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue AVSOLA® if a patient develops a serious infection or sepsis.

Reported infections include:

- **Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before AVSOLA® use and during therapy. Treatment for latent infection should be initiated prior to AVSOLA® use.**
- **Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis and cryptococcosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.**
- **Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella, Listeria, and Salmonella.**

The risks and benefits of treatment with AVSOLA® should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with AVSOLA®, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy, who are on treatment for latent TB, or who were previously treated for TB infection.

Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with co-morbid conditions and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab products included pneumonia, cellulitis, abscess, and skin ulceration.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab products. Approximately half of these cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.

Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been

fatal. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with AVSOLA®, especially in these patient types.

In clinical trials of all TNF inhibitors, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn's disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF inhibitors, including infliximab products, more cases of other malignancies were observed compared with controls. The rate of these malignancies among patients treated with infliximab products was similar to that expected in the general population, whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. As the potential role of TNF inhibitors in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

A population-based retrospective cohort study found a 2- to 3-fold increase in the incidence of invasive cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-naïve patients or the general population, particularly those over 60 years of age. A causal relationship between infliximab products and cervical cancer cannot be excluded. Periodic screening should continue in women treated with AVSOLA®.

CONTRAINDICATIONS

The use of AVSOLA® at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. AVSOLA® is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab or any of the inactive ingredients of AVSOLA® or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness).

HEPATITIS B REACTIVATION

TNF inhibitors, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating AVSOLA®. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing AVSOLA® for patients identified as carriers of HBV and monitor closely for active HBV infection during and following termination of therapy with AVSOLA®. Discontinue AVSOLA® in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution

IMPORTANT SAFETY INFORMATION (cont'd)

when considering resumption of TNF-blocker therapy and monitor patients closely.

HEPATOTOXICITY

Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported in patients receiving infliximab products postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥ 5 times the upper limit of normal) develop, AVSOLA® should be discontinued, and a thorough investigation of the abnormality should be undertaken.

HEART FAILURE

In a randomized, placebo-controlled study in patients with moderate or severe heart failure (NYHA Functional Class III/IV), higher mortality rates and a higher risk of hospitalization were observed at Week 28 at a dose of 10 mg/kg and higher rates of cardiovascular events were observed at both 5 mg/kg and 10 mg/kg. There have been postmarketing reports of new onset and worsening heart failure, with and without identifiable precipitating factors. Patients with moderate or severe heart failure taking infliximab (≤ 5 mg/kg) or patients with mild heart failure should be closely monitored and treatment should be discontinued if new or worsening symptoms appear.

HEMATOLOGIC REACTIONS

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported in patients receiving infliximab products. The causal relationship to infliximab product therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of AVSOLA® in patients who develop significant hematologic abnormalities.

HYPERSENSITIVITY

Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset. Anaphylaxis, urticaria, dyspnea, and hypotension have occurred in association with infusions of infliximab products. Medications for the treatment of hypersensitivity reactions should be available.

CARDIOVASCULAR AND CEREBROVASCULAR REACTIONS DURING AND AFTER INFUSION

Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of infliximab product infusion. Cases of transient visual loss have been reported during or within 2 hours of infusion of infliximab. Monitor patients during infusion and if a serious reaction occurs, discontinue infusion. Manage reactions according to signs and symptoms.

NEUROLOGIC REACTIONS

Agents that inhibit TNF have been associated with CNS manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome. Exercise caution when considering AVSOLA® in patients with these disorders and consider discontinuation if these disorders develop.

CONCURRENT ADMINISTRATION WITH OTHER BIOLOGICS

Concomitant use of AVSOLA® with anakinra, abatacept, tocilizumab, or other biologics used to treat the same conditions as AVSOLA® is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.

AUTOIMMUNITY

Treatment with infliximab products may result in the formation of autoantibodies and in the development of a lupus-like syndrome. Discontinue treatment with AVSOLA® if symptoms of a lupus-like syndrome develop.

VACCINATIONS AND USE OF LIVE VACCINES/ THERAPEUTIC INFECTIOUS AGENTS

Bring patients up to date with all vaccinations prior to initiating AVSOLA®. Live vaccines or therapeutic infectious agents should not be given with AVSOLA® due to the possibility of clinical infections, including disseminated infections.

At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed *in utero* to infliximab products.

ADVERSE REACTIONS

In clinical trials with infliximab products, the most common adverse reactions occurring in $>10\%$ of patients included infections (eg, upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.

Please [click here for full Prescribing Information](#).



BUSINESS CARD SLEEVE

Your Amgen representative can connect you with an Access Specialist or call **(866)-772-6436**, Monday - Friday, 8:00am - 8:00pm ET

References: **1.** AVSOLA® (infliximab-axxq) prescribing information, Amgen. **2.** CMS, Part B Inflation Rebate Guidance: Use of the 340B Modifiers, December 20, 2022, available at <https://www.cms.gov/files/document/part-b-inflation-rebate-guidance340b-modifierfinal.pdf>. Accessed May 17, 2023. **3.** CMS, Discarded Drugs and Biologicals – JW Modifier and JZ Modifier Policy FAQs (January 2023), available at <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>. Accessed May 17, 2023. **4.** Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions. <https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-1-2020-drugs-and-biologicals.pdf>. Accessed May 19, 2023. **5.** American Medical Association. *CPT® 2020 Professional Edition*. American Medical Association; 2019. **6.** Noridian Healthcare Solutions. Revenue Codes. <https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes>. Accessed May 19, 2023. **7.** Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. <https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2020-ICD-10-CM-Code-Tables.zip>. Accessed May 19, 2023.

Reimbursement Disclaimer

This resource is intended as a reference for coding and billing for product and associated services. Coding and coverage policies change periodically. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

Please see Important Safety Information on pages 6-7 and [click here for full Prescribing Information](#).

Please visit [AVSOLA.com](https://www.avsula.com) for additional information and resources.

Call **1-800-77-AMGEN (1-800-772-6436)** if you have questions about ordering and accessing AVSOLA®.

AMGEN®

AVSOLA® is a trademark of Amgen Inc.
© 2023 Amgen Inc. All rights reserved. USA-710-80613 05/23

